Gland Pharma Ltd (NSE:GLAND) Q4 FY25 Earnings Call Highlights: Navigating Challenges and ...
In This Article:
-
Q4 FY25 Consolidated Revenue: INR14,249 million.
-
Q4 FY25 Consolidated EBITDA: INR3,475 million, reflecting a 24% margin.
-
Base Business Revenue (Excluding Cenexi) Q4 FY25: INR10,332 million, a 12% year-over-year decline.
-
Base Business EBITDA Margin Q4 FY25: 38%, up from 36% in the prior year.
-
Full Year FY25 Consolidated Revenue: INR56,165 million.
-
Full Year FY25 Consolidated EBITDA: INR12,689 million, resulting in a 23% margin.
-
Base Business Revenue (Excluding Cenexi) Full Year FY25: INR41,248 million.
-
Base Business EBITDA Full Year FY25: INR14,451 million, translating to a 35% margin.
-
Q4 FY25 Gross Margin: 66%, up from 61% in Q4 FY24.
-
Q4 FY25 Net Profit: INR1,865 million, a 3% decrease compared to Q4 FY24.
-
Full Year FY25 Net Profit: INR6,985 million, a 10% decline from the previous year.
-
Q4 FY25 R&D Expenditure: INR503 million, 4.9% of base business revenue.
-
Full Year FY25 R&D Expenditure: INR1,922 million, 4.7% of base business revenue.
-
Cash and Cash Equivalents as of March 31, 2025: INR25,562 million.
-
Net Cash Position (After Cenexi's Debt): INR22,870 million.
-
Cash Flow from Operations FY25: INR9,147 million.
-
CapEx Q4 FY25: INR886 million.
-
Full Year FY25 CapEx: INR3,938 million.
Release Date: May 20, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Gland Pharma Ltd (NSE:GLAND) is expanding its geographical presence into emerging markets such as Africa, the Middle East, Latin America, and Asia Pacific, which presents substantial market opportunities.
-
The company has made significant progress in expanding its manufacturing capabilities, including the successful entry into the GLP-1 segment with the launch of Liraglutide.
-
Gland Pharma Ltd (NSE:GLAND) has a robust R&D pipeline with 71 new NDAs targeting a $5.7 billion total addressable market, focusing on major therapies like ophthalmology, CNS, and cardiology.
-
The company is experiencing significant momentum in attracting major pharmaceutical companies for high-value formats like dry powders, with several new CMO projects initiated.
-
Gland Pharma Ltd (NSE:GLAND) is actively exploring inorganic opportunities via mergers and acquisitions to accelerate complex product development and expand its product range.
Negative Points
-
The company faced near-term growth challenges, particularly due to reciprocal tariffs announced by the US administration, creating uncertainty for Indian pharmaceutical companies.
-
Cenexi, a subsidiary of Gland Pharma Ltd (NSE:GLAND), has underperformed, with foundational groundwork for its turnaround in place but results falling short of expectations.
-
The company's base business reported a 12% year-over-year decline in revenues for Q4 FY25, primarily due to higher marginal realization in the previous year and tender losses in RoW markets.
-
Despite new product launches, the US business has been relatively flat, with revenue growth constrained by reduced material costs and end market prices.
-
Cenexi's performance was impacted by lower production at the Fontenay facility due to ongoing remediation activities and equipment breakdowns, leading to reduced shipments and lower sales figures.